PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Int J Med Sci. 2021 Jan 1;18(1):256-269. doi: 10.7150/ijms.48123. eCollection 2021.
Ampullary cancer is a rare periampullary cancer currently with no targeted therapeutic agent. It is important to develop a deeper understanding of the carcinogenesis of ampullary cancer. We attempted to explore the characteristics of ampullary cancer in our dataset and a public database, followed by a search for potential drugs. We used a bioinformatics pipeline to analyze complementary (c)DNA microarray data of ampullary cancer and surrounding normal duodenal tissues from five patients. A public database from the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) was applied for external validation. Bioinformatics tools used included the Gene Set Enrichment Analysis (GSEA), Database for Annotation, Visualization and Integrated Discovery (DAVID), MetaCore, Kyoto Encyclopedia of Genes and Genomes (KEGG), Hallmark, BioCarta, Reactome, and Connectivity Map (CMap). In total, 9097 genes were upregulated in the five ampullary cancer samples compared to normal duodenal tissues. From the MetaCore analysis, genes of peroxisome proliferator-activated receptor alpha () and retinoid X receptor ()-regulated lipid metabolism were overexpressed in ampullary cancer tissues. Further a GSEA of the KEGG, Hallmark, Reactome, and Gene Ontology databases revealed that and lipid metabolism-related genes were enriched in our specimens of ampullary cancer and in the NCBI GSE39409 database. Expressions of messenger (m)RNA and the PPAR-α protein were higher in clinical samples and cell lines of ampullary cancer. US Food and Drug Administration (FDA)-approved drugs, including alvespimycin, trichostatin A (a histone deacetylase inhibitor), and cytochalasin B, may have novel therapeutic effects in ampullary cancer patients as predicted by the CMap analysis. Trichostatin A was the most potent agent for ampullary cancer with a half maximal inhibitory concentration of < 0.3 μM. According to our results, upregulation of and lipid metabolism-related genes are potential pathways in the carcinogenesis and development of ampullary cancer. Results from the CMap analysis suggested potential drugs for patients with ampullary cancer.
壶腹癌是一种罕见的胰周癌,目前尚无靶向治疗药物。深入了解壶腹癌的发生机制非常重要。我们试图在本数据集和公共数据库中探索壶腹癌的特征,并寻找潜在的药物。我们使用生物信息学管道分析了来自五名患者的壶腹癌和周围正常十二指肠组织的互补 (c)DNA 微阵列数据。还应用了来自国家生物技术信息中心基因表达综合数据库 (NCBI GEO) 的公共数据库进行外部验证。使用的生物信息学工具包括基因集富集分析 (GSEA)、数据库注释、可视化和综合发现 (DAVID)、MetaCore、京都基因与基因组百科全书 (KEGG)、Hallmark、BioCarta、Reactome 和连接图谱 (CMap)。与正常十二指肠组织相比,这五个壶腹癌样本中共有 9097 个基因上调。MetaCore 分析显示,过氧化物酶体增殖物激活受体-α () 和视黄醇 X 受体 () 调节的脂质代谢基因在壶腹癌组织中过表达。进一步对 KEGG、Hallmark、Reactome 和基因本体数据库进行 GSEA 分析显示,和脂质代谢相关基因在我们的壶腹癌标本和 NCBI GSE39409 数据库中富集。在壶腹癌的临床样本和细胞系中,信使 (m)RNA 和 PPAR-α 蛋白的表达更高。CMap 分析预测,阿维泊苷、曲古抑菌素 A(组蛋白去乙酰化酶抑制剂)和细胞松弛素 B 等美国食品和药物管理局 (FDA) 批准的药物可能对壶腹癌患者具有新的治疗作用。曲古抑菌素 A 对壶腹癌的抑制作用最强,半数最大抑制浓度 < 0.3 μM。根据我们的结果,上调的 和脂质代谢相关基因可能是壶腹癌发生和发展的潜在途径。CMap 分析结果提示了壶腹癌患者的潜在药物。